Education
About Us
Working with TipRanks
Follow Us
Unity Biotechnology Inc (UBX)
NASDAQ:UBX
UBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.94 - $3.10
Previous CloseN/A
Volume348.46K
Average Volume (3M)178.75K
Market Cap
$19.23M
Enterprise Value$20.16M
Total Cash (Recent Filing)$7.58M
Total Debt (Recent Filing)$23.54M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
May 13, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding16,867,647
10 Day Avg. Volume292,001
30 Day Avg. Volume178,750
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.34
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$4.00Price Target Upside250.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Unity Biotechnology News
PremiumCompany Announcements
Unity Biotechnology Appoints Dr. Yehia Hashad to Board
---
Bulls Say, Bears Say
Bulls Say
Drug PerformanceUBX1325 explicitly achieved non-inferiority to aflibercept for 9 out of 10 time points through 36 weeks, reflecting a completely novel approach in retinal disease.
EarningsThe analyst's recommendation remains 'Outperform' with a price target of $6.00, indicating confidence in the stock's future performance.
Treatment OptionUBX1325 showed outperformance of aflibercept for patients with less aggressive disease, suggesting a prospective option for 2L treatment subsequent to standard of care anti-VEGF.
Bears Say
Data ImbalanceThere were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.
Endpoint MissThe study missed the primary endpoint of non-inferiority vs aflibercept using the average of 20-week and 24-week BCVA letters change from baseline.
Trial ResultsThe Phase 2B ASPIRE study of intravitreal foselutoclax (UBX1325) in diabetic macular edema patients did not meet the non-inferiority analysis specifically at the average of weeks 20 and 24 for the primary analysis.
---
Ownership Overview
9.99% Insiders
4.64% Mutual Funds
11.96% Other Institutional Investors
69.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UBX FAQ
What was Unity Biotechnology Inc’s price range in the past 12 months?
Unity Biotechnology Inc lowest stock price was $0.94 and its highest was $3.10 in the past 12 months.
What is Unity Biotechnology Inc’s market cap?
Unity Biotechnology Inc’s market cap is $19.23M.
When is Unity Biotechnology Inc’s upcoming earnings report date?
Unity Biotechnology Inc’s upcoming earnings report date is May 13, 2025 which is in 43 days.
How were Unity Biotechnology Inc’s earnings last quarter?
Unity Biotechnology Inc released its earnings results on Mar 07, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.114.
Is Unity Biotechnology Inc overvalued?
According to Wall Street analysts Unity Biotechnology Inc’s price is currently Undervalued.
Does Unity Biotechnology Inc pay dividends?
Unity Biotechnology Inc does not currently pay dividends.
What is Unity Biotechnology Inc’s EPS estimate?
Unity Biotechnology Inc’s EPS estimate is -0.35.
How many shares outstanding does Unity Biotechnology Inc have?
Unity Biotechnology Inc has 16,867,647 shares outstanding.
What happened to Unity Biotechnology Inc’s price movement after its last earnings report?
Unity Biotechnology Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Unity Biotechnology Inc?
Currently, no hedge funds are holding shares in UBX
---
Unity Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (250.88% Upside)
$4.00 (250.88% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.48%
12-Months-Change
Fundamentals
Return on Equity
-148.97%
Trailing 12-Months
Asset Growth
-38.48%
Trailing 12-Months
Company Description
Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
---
UBX Stock 12 Month Forecast
Average Price Target
$4.00
▲(250.88% Upside)
Technical Analysis
Oncolytics Biotech
―
Sarepta Therapeutics
―
Curis
―
Fate Therapeutics
―
Bioxcel Therapeutics
―
Best Analysts Covering UBX
1 Year
1 Year Success Rate
2/26 ratings generated profit
1 Year Average Return
-45.15%
reiterated a buy rating 7 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -45.15% per trade.
---